Link to Full Article Arecor innovative product formulations applied to oncology and rare orphan diseases Cambridge, UK, 19 March 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collaboration with a US-based clinical stage biotechnology company. Under the collaboration, Arecor […]
Link to Full Article Arecor formulated biosimilar product progressing through clinical studies Cambridge, UK., 25 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered […]
Link to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]
Link to Full Article Product designed to provide safer, more immediate treatment option for patients London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing […]
Link to Full Article Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment Cambridge, UK., 5th December 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. […]
Link to Full Article Cambridge, UK., 22 October 2019: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will […]
Link to Full Article HEADLINE DATA READOUT EXPECTED Q4 2019 Cambridge, UK.,4 October 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. Arecor’s AT247 […]
Link to Full Article Cambridge, UK., 9th July 2019: Arecor Ltd (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company. Under this […]
Link to Full Article Arecor, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, announces the initiation of its AT247 Phase I clinical trial and an important next step in the Company’s strategy to develop even faster acting insulins targeted at […]
Link to Full Article Cambridge, UK., 7th May 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting […]